Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi
Life Sciences (2022) Vol. 310, pp. 121083-121083
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Extracellular vesicle–based drug delivery in cancer immunotherapy
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 11, pp. 2790-2806
Open Access | Times Cited: 39
The role of microRNA-185 in the pathogenesis of human diseases: A focus on cancer
Safoora Pordel, Motahare Khorrami, Fatemeh Saadatpour, et al.
Pathology - Research and Practice (2023) Vol. 249, pp. 154729-154729
Open Access | Times Cited: 30
B7-H3 immunoregulatory roles in cancer
Keywan Mortezaee
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114890-114890
Open Access | Times Cited: 26
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Muhua Chen, Lei Bie, Ying Jieer
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115514-115514
Open Access | Times Cited: 25
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
Claudia Giannotta, Federica Autino, Massimo Massaia
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 24
Targeting tumor-infiltrating tregs for improved antitumor responses
Diyuan Qin, Yugu Zhang, Pei Shu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Tao Lei, Yazhuo Wang, Yuchen Zhang, et al.
Leukemia (2024)
Open Access | Times Cited: 16
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access | Times Cited: 1
microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance
Mehdi Fattahi, Delsuz Rezaee, Fatemeh Fakhari, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 22
Tumor-educated platelets
Sajad Najafi, Yahya Asemani, Jamal Majidpoor, et al.
Clinica Chimica Acta (2023) Vol. 552, pp. 117690-117690
Closed Access | Times Cited: 17
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
Arian Charehjoo, Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2023) Vol. 118, pp. 110032-110032
Closed Access | Times Cited: 16
Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies
Sajad Najafi, Keywan Mortezaee
Life Sciences (2023) Vol. 338, pp. 122387-122387
Closed Access | Times Cited: 16
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
Paraskevi Vryza, Timo Fischer, Elena Mistakidi, et al.
Translational Oncology (2023) Vol. 38, pp. 101788-101788
Open Access | Times Cited: 15
Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated
Zara Karami, Keywan Mortezaee, Jamal Majidpoor
International Immunopharmacology (2023) Vol. 122, pp. 110648-110648
Open Access | Times Cited: 11
Alternative immune checkpoints in immunoregulatory profile of cancer stem cells
Keywan Mortezaee, Jamal Majidpoor
Heliyon (2023) Vol. 9, Iss. 12, pp. e23171-e23171
Open Access | Times Cited: 11
The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma
Mateusz Olbromski, Monika Mrozowska, Aleksandra Piotrowska, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 4
Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy
Muhammad Shahab, Haitham Al‐Madhagi, Guojun Zheng, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses
Keywan Mortezaee, Jamal Majidpoor
Heliyon (2023) Vol. 9, Iss. 3, pp. e14566-e14566
Open Access | Times Cited: 7
Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors
Keywan Mortezaee, Jamal Majidpoor
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114621-114621
Open Access | Times Cited: 4
Inhibition of Tumoral VISTA to Overcome TKI Resistance via Downregulation of the AKT/mTOR and JAK2/STAT5 Pathways in CML
Kexin Ai, Mu Chen, Liang Zhao, et al.
Biomolecules & Therapeutics (2024) Vol. 32, Iss. 5, pp. 582-600
Closed Access | Times Cited: 1
Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review
Hori Ghaneialvar, Saleheh Jahani, Elham Hashemi, et al.
Human Immunology (2024) Vol. 86, Iss. 1, pp. 111209-111209
Closed Access | Times Cited: 1
A macropinocytosis-related gene signature predicts the prognosis and immune microenvironment in hepatocellular carcinoma
Xinjiang Ding, Tao Yao, Xi Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4
Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee
Pathology - Research and Practice (2023) Vol. 247, pp. 154583-154583
Closed Access | Times Cited: 3
Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
Paulina Chmiel, Katarzyna Gęca, Adam Michalski, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9945-9945
Open Access | Times Cited: 3
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
Wandi Li, Zhaopei Liu, Kaifeng Jin, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top